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Abstract
Background:  Anxiety and depression are among the most frequently-observed psychiatric
symptoms associated with nicotine (NC). In addition to the similarity to other addictive drugs,
these NC-induced symptoms are characteristic in that the opposite behavioral effects, i.e.
anxiolytic and antidepressant effects, which may reinforce the habitual use of NC, have also been
reported. In the present study, the time course of anxiety- and depression-related behavioral
alterations was examined in mice. Furthermore, based on the reported similarity in the mechanisms
responsible for NC-induced anxiety- and depression-related symptoms, as well as the contribution
of brain cannabinoid (CB) receptors to these behavioral symptoms, the effects of anxiolytics and
CB receptor ligands (CBs) against these behavioral symptoms were investigated.
Results: Repeated subcutaneous NC treatments (0.3 mg/kg, 4 days), compared with a single
treatment (0.5 mg/kg), caused both prolonged anxiogenic effects in the elevated plus-maze test, and
prolonged depressive effects in the forced swimming test, even at 120 min time point after the last
NC treatment. A transient anxiolytic preference for open arms was also observed in the elevated
plus-maze test. Among the anxiolytics and CBs, the serotonin 1A (5-HT1A) antagonist WAY
100135 and the endogenous mixed CB agonist/antagonist virodhamine (VD), when administered
intraperitoneally before each NC treatment, provided the strongest antagonistic effects against the
anxiety-related symptoms. However, against the depression-related symptoms, only VD provided
significant antagonistic effects in both single and repeated treatment groups.
Conclusion: The present results support the presence of a chronological overlap of NC-induced
anxiety- and depression-related behavioral symptoms, and the contribution of brain CB receptors
to these behavioral symptoms. The repeated NC-induced prolongation of these behavioral
symptoms and the early transient anxiolytic behavioral alterations support an increased possibility
of the habitual use of NC. Furthermore, based on the antagonistic effects of VD, one can predict
that the characteristic effects on brain CB receptors as a mixed CB agonist/antagonist contributed
to its therapeutic effects as both an anxiolytic and an antidepressant.
Background
Anxiety and depression are among the most frequently-
observed psychiatric effects associated with nicotine (NC)
in tobacco smoking [1-4], similar to cases using well-
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known addictive psychostimulants such as cocaine [5,6].
These NC-related symptoms have been reported as direct
effects of NC, which disappear following smoking cessa-
tion [2,4] or as withdrawal symptoms [1,3]. In experimen-
tal models, similar to the anxiety- and depression-related
behavioral symptoms from other causes, brain GABAergic
and serotonin (5-HT) neurons contribute to the anxio-
genic effects of NC [7-9], whereas brain monoamine neu-
rons contribute to its depressive effects [10]. However,
since the distribution of brain nicotinic acetylcholine
receptors (nAChRs), the primary targets of NC, is wide-
spread and functional interactions between the above
indicated anxiety- and depression-related neurons and
nAChRs have been demonstrated [11-13], different mech-
anisms mediating anxiety- and depression-related behav-
iors as compared to behaviors caused by the other
addictive drugs can be predicted. For example, NC also
causes anxiolytic and antidepressant effects in both
humans and animals, depending on dose, time after use,
and previous exposure to NC [14-17], and these effects
seem to reinforce the habitual use of NC. Furthermore,
because of the overlapped distributions of nAChRs and
the targets of other abused drugs such as DA neurons, the
targets of addictive psychostimulants, and the similarity
of the effects of NC to those of other addictive drugs
[18,19], NC is thought to play a role as a trigger for other
abused drugs [20].
The anxiogenic effects of NC are, like the anxiety-related
behavioral symptoms from other causes, attenuated by
benzodiazepine (BZ)- and 5-HT-related anxiolytics in sev-
eral animal models [7-9]. However, based on the above-
explained characteristic pharmacological effects of NC
(i.e. the induction of contrary behavioral symptoms
depending on the treatment conditions) and the wide-
spread distributions of nAChRs, it is possible that the role
of these BZ- and 5-HT-related drugs as anxiolytics may be
modified in NC treatment groups. Furthermore, although
some contributions of GABAergic and 5-HT neurons, the
targets of BZ- and 5-HT-related anxiolytics, to depression-
related behavioral symptoms have also been suggested
[21,22], the effects of these drugs against the NC-induced
depression-related behavioral symptoms have not been
studied. Recently, functional interactions between brain
cannabinoid (CB) receptors and nAChRs have been dem-
onstrated, and modifications of the behavioral effects of
NC by CB receptor ligands (cannabinoids: CBs), e.g.
attenuation of NC-induced anxiety-related behavioral
symptoms by a CB agonist, have been elucidated [23-25].
Functional interactions between brain CB receptors and
receptors related to anxiety and/or depression (e.g. modi-
fications of GABAergic, serotonergic, and monoaminergic
neurotransmission by CBs, etc.) have also been demon-
strated [26-28]. Furthermore, several endogenous CBs
were discovered, and their potential therapeutic uses,
including anxiolytic and antidepressant effects reported
for endogenous agonists such as anandamide, have been
suggested [28-30].
In the present study, based on the predicted peculiarity of
the behavioral effects of NC, the time course of anxiety-
related (elevated plus-maze test) and depression-related
(forced swimming test) behavioral alterations were exam-
ined in both single and repeated treatment groups of
mice, and the characteristics of the appearance of these
behavioral symptoms, which may be correlated with the
habitual use of NC, were investigated. Furthermore, one
of the objectives of the present study was to examine the
effects of both conventional BZ- and 5-HT-related anxio-
lytics and CBs, some of which can function as both anxi-
olytics and antidepressants, against the NC-induced
anxiety- and depression-related behavioral symptoms,
and to investigate the possible use of these drugs as both
anxiolytics and antidepressants.
Results
Time course of NC-induced anxiety-related behavioral 
alterations
For the single NC (0.5 mg/kg) treatment group (Fig. 1a),
at 30 min time point, behavioral alterations derived from
an anxiety-related attenuated preference for open arms
(significantly attenuated number of entries into and time
spent in open arms, and increased latency to first open
arm entry) were observed for each parameter value in the
elevated plus-maze test. On the other hand, at 60 min
time point, there was a significantly increased amount of
time spent in open arms and an attenuated latency to first
open arm entry, suggesting attenuations in anxiety-related
behavioral alterations and anxiolytic effects of NC. With
respect to the total number of entries into arms, there was
no significant difference as compared to the control group
at 30 min time point. However, at 60 min time point, a
significant attenuation in the total number of entries into
arms, indicating an increased ratio of the number of
entries into open arms and suggesting anxiolytic effects of
NC, was observed. All of the altered parameter values
returned to the control levels at 120 time point.
For the repeated NC (0.3 mg/kg, 4 days) treatment group
(Fig. 1b), at 30 min time point, a tendency towards an
increased amount of time spent in open arms and a signif-
icantly attenuated latency to first open arm entry, suggest-
ing anxiolytic effects of NC, was observed. On the other
hand, at 60 min time point, behavioral alterations derived
from an anxiety-related preference for closed arms were
observed for each parameter value. For the total number
of entries into arms, a significant attenuation, suggesting
anxiolytic effects of NC, was observed at 30 min time
point. However, at 60 min time point, there was no signif-
icant difference as compared to the control group. At 120BMC Neuroscience 2007, 8:76 http://www.biomedcentral.com/1471-2202/8/76
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min time point, the anxiety-related attenuated preference
for open arms persisted.
In both single and repeated treatment groups, the ANOVA
analyses revealed significant main effects of NC treatment
for each parameter value [see Additional file 1]. Further-
more, significant main effects of test time and interactions
between NC treatment and test time were also observed
for some parameter values, which indicated some time-
dependent changes.
Time course of NC-induced depression-related behavioral 
alterations
For the single NC treatment group (Fig. 2a), at 30 min
time point, depression-related alterations in swimming
behaviors (significantly attenuated time until immobility
and attenuated activity counts) were observed for each
parameter value in the forced swimming test. However, all
of the altered parameter values returned to the control lev-
els at 60 min time point.
For the repeated NC treatment group (Fig. 2b), depres-
sion-related alterations in the swimming behaviors were
observed at 30, 60, and 120 min time points.
In both single and repeated treatment groups, the ANOVA
analyses revealed significant main effects of NC treatment
for each parameter value [see Additional file 1]. Further-
more, significant main effects of test time and interactions
between NC treatment and test time were also observed in
Time courses of nicotine (NC)-induced depression-related  behavioral alterations in the forced swimming test Figure 2
Time courses of nicotine (NC)-induced depression-
related behavioral alterations in the forced swim-
ming test. The parameter values at 30, 60 and 120 min time 
points after the NC treatment are shown for the single (a) 
and repeated (b) NC treatment groups. Data represent 
means ± SD (n = 7 for each group). The symbols for differ-
ences are the same as in the other figures.
a) Single NC treatment group 
1. Time until immobility (min)
0
2.5
5
30 60 120
Experiment time (min)
Control NC
a
 
2. Activity counts (counts/10min)
0
2000
4000
30 60 120
Experiment time (min)
a
   
b) Repeated NC treatment group 
1. Time until immobility (min)
0
2.5
5
30 60 120
Experiment time (min)
Control NC
a a a
 
2. Activity counts (counts/10min)
0
2000
4000
30 60 120
Experiment time (min)
a a a
   
Time courses of nicotine (NC)-induced anxiety-related  behavioral alterations in the elevated plus-maze test Figure 1
Time courses of nicotine (NC)-induced anxiety-
related behavioral alterations in the elevated plus-
maze test. The parameter values at 30, 60 and 120 min 
time points after the NC treatment are shown for the single 
(a) and repeated (b) NC treatment groups. Data represent 
means ± SD (n = 7 for each group). A, a: significant (p < 0.05) 
increase (A) or attenuation (a) as compared to the control 
group.
a) Single NC treatment group 
1. Number of entries into open arms
0
10
20
30 60 120
Experiment time (min)
Control NC
a
 
2. Total number of entries into arms
0
25
50
30 60 120
Experiment time (min)
a
 
3. Time spent in open arms (sec)
0
50
100
150
30 60 120
Experiment time (min)
A
a
  
4. Latency to first open arm entry (sec)
0
25
50
30 60 120
Experiment time (min)
A
a
 
b) Repeated NC treatment group 
1. Number of entries into open arms
0
10
20
30 60 120
Experiment time (min)
Control NC
a
a a
 
2. Total number of entries into arms
0
25
50
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Experiment time (min)
a
 
3. Time spent in open arms (sec)
0
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Experiment time (min)
a a
 
4. Latency to first open arm entry (sec)
0
25
50
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Experiment time (min)
A
a
A
   BMC Neuroscience 2007, 8:76 http://www.biomedcentral.com/1471-2202/8/76
Page 4 of 9
(page number not for citation purposes)
the single treatment group, which indicated some time-
dependent changes.
Effects of anxiolytics or CBs on NC-induced anxiety-
related behavioral alterations
For the single NC treatment group (Fig. 3a), effects of anx-
iolytics or CBs were examined against NC-induced anxi-
ety-related behavioral alterations observed at 30 min time
point in the elevated plus-maze test. For pairwise compar-
isons, in the groups co-treated with the anxiolytics
diazepam (DZ), WAY100135 dihydrochloride (WAY),
and ondansetron hydrochloride (ON), and the CBs anan-
damide (arachidonylethanolamide: AEA), 2-arachido-
nylglycerol (ARA), virodhamine (VD), and CP55940 ((-)-
cis-3- [2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-
(3-hydroxypropyl) cyclohexanol) (CP), some suppres-
sions of the anxiety-related behavioral alterations (sup-
pressions of the attenuated number of entries into and
time spent in open arms, and/or increased latency to first
open arm entry) as compared to the NC-only group were
observed. In particular, in the NC-WAY and NC-VD
groups, all of the parameter values returned to the control
levels. On the other hand, no significant alterations were
observed, either with or without the co-treatment with
anxiolytics or CBs, in the total number of entries into
arms.
For the repeated NC treatment group (Fig. 3b), effects of
anxiolytics or CBs were examined against NC-induced
anxiety-related behavioral alterations observed at 60 min
time point. For pairwise comparisons, in the groups co-
treated with DZ, WAY, ON, AEA, and VD, some suppres-
sions of the anxiety-related behavioral alterations as com-
pared to the NC-only group were observed. In particular,
in the NC-WAY and NC-VD groups, all of the parameter
values returned to the control levels. On the other hand,
no significant alterations were observed, either with or
without the co-treatment with anxiolytics or CBs, for the
total number of entries into arms.
In both single and repeated treatment groups, the ANOVA
analyses revealed significant main effects of NC treatment
for each parameter value except for the total number of
entries into arms [see Additional file 1]. Furthermore, sig-
nificant main effects of anxiolytics or CBs treatment and
interactions between NC and anxiolytics or CBs treatment
were also observed for the time spent in open arms and
the latency to first open arm entry in the single treatment
group, and for each parameter value except for the total
number of entries into arms in the repeated treatment
group, which indicated some influences of the anxiolytics
and/or CBs on the NC-induced anxiety-related behavioral
alterations. However, in each anxiolytic- or CB-only
group, no significant alterations in each parameter value
were observed (not shown in the figure).
Effects of anxiolytics or CBs on NC-induced depression-
related behavioral alterations
For the single NC treatment group (Fig. 4a), effects of anx-
iolytics or CBs were examined against NC-induced depres-
sion-related behavioral alterations observed at 30 min
time point in the forced swimming test. For pairwise com-
parisons, in the groups co-treated with AEA and VD, some
suppressions of the depression-related behavioral altera-
tions (suppressions of the attenuated time until immobil-
ity and/or attenuated activity counts) as compared to the
NC-only group were observed. In particular, in the NC-VD
group, all of the parameter values returned to the control
levels.
Effects of anxiolytics or cannabinoid receptor ligands (can- nabinoids: CBs) on nicotine (NC)-induced anxiety-related  behavioral alterations Figure 3
Effects of anxiolytics or cannabinoid receptor ligands 
(cannabinoids: CBs) on nicotine (NC)-induced anxi-
ety-related behavioral alterations. The parameter values 
at 30 min time point for the single NC treatment group (a) 
and at 60 min time point for the repeated NC treatment 
group (b) are shown. Data represent means ± SD (n = 7 for 
each group). The symbols for differences are the same as the 
other figures. The abbreviations of the co-administered anxi-
olytics or CBs as demonstrated below the X-axis are noted 
in the text.
a) Single NC treatment group 
1. Number of entries into open arms
0
10
20
Control NC-only DZ WAY ON AEA ARA VD CP
a
a
2. Total number of entries into arms
0
25
50
Control NC-only DZ WAY ON AEA ARA VD CP
3. Time spent in open arms (sec)
0
50
100
Control NC-only DZ WAY ON AEA ARA VD CP
a
4. Latency to first open arm entry (sec)
0
25
50
Control NC-only DZ WAY ON AEA ARA VD CP

A
A A A AA
     
b) Repeated NC treatment group 
1. Number of entries into open arms
0
10
20
Control NC-only DZ WAY ON AEA ARA VD CP
a
a
a
2. Total number of entries into arms
0
25
50
Control NC-only DZ WAY ON AEA ARA VD CP
3. Time spent in open arms (sec)
0
50
100
Control NC-only DZ WAY ON AEA ARA VD CP
a
a a
4. Latency to first open arm entry (sec)
0
25
50
Control NC-only DZ WAY ON AEA ARA VD CP
A
A A A
A A
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For the repeated NC treatment group (Fig. 4b), effects of
anxiolytics or CBs were examined against NC-induced
depression-related behavioral alterations observed at 30
min time point. For pairwise comparisons, only in the
group co-treated with VD, significant recoveries in the
depression-related behavioral alterations to the control
levels were observed for each parameter value.
In both single and repeated treatment groups, the ANOVA
analyses revealed significant main effects of NC and anxi-
olytics or CBs treatment for each parameter value [see
Additional file 1]. Furthermore, significant interactions
between NC and anxiolytics or CBs treatment were also
observed for the activity counts, which indicated some
influences of the anxiolytics and/or CBs on the NC-
induced depression-related behavioral alterations. How-
ever, in each anxiolytic- or CB-only group, no significant
alterations in each parameter value were observed (not
shown in the figure).
Discussion
The present experiments demonstrated chronologically
overlapped occurrences of NC-induced anxiety- and
depression-related behavioral alterations in both single
and repeated treatment groups of mice. On the other
hand, although some correlations in the underlying
mechanisms could be predicted as described above, there
were also some differences in the time courses between
the two kinds of behavioral alterations (Figs. 1 and 2).
Furthermore, an absence of antidepressant effects of many
anxiolytics against the NC-induced depressed swimming
behaviors was revealed (Fig. 4). With respect to the
involved sites of the primary target nAChRs, the contribu-
tion of both alpha7 and alpha4beta2 subunits was sug-
gested for the anxiogenic effects of NC [9], whereas the
absence of any contribution of alpha7 subunit was dem-
onstrated for the depressive effects of NC [31]. However,
it has been reported that both anxiety- and depression-
related behavioral alterations are accompanied by the
increased secretion of stress hormones such as corticoster-
oids through the activation of the hypothalamic-pituitary-
adrenal (HPA) axis [32,33]. The transient but simultane-
ous occurrences of anxiety- and depression-related behav-
ioral alterations observed in the present results may be
correlated with the predominant influence of the stress-
related endocrine system.
As explained above, the anxiogenic effects are evaluated
by an attenuated preference for open arms in the elevated
plus-maze test, whereas depressive effects are evaluated by
suppressed swimming behaviors (attenuated time until
immobility and attenuated activity counts) in the forced
swimming test. In previous studies, the opposite behavio-
ral effects, i.e. anxiolytic and antidepressant effects, were
demonstrated for NC [16,17]. Under the present condi-
tions, only depression-related suppressed swimming
behaviors were observed (Fig. 2), whereas anxiolytic
effects were observed in both single and repeated treat-
ment groups at different time points. Although the under-
lying mechanisms have not been elucidated sufficiently,
some contributions of temporary modifications of the
endogenous 5-HT and CB system have been suggested for
the occurrence of anxiolytic effects [16,24]. Time-depend-
ent modifications in the stress-related endocrine system
[33] also seem to correlate with the temporary occurrence
of NC-induced anxiolytic effects. Nevertheless, based on
animal models of NC treatment in which anxiolytic and
antidepressant effects were predominantly observed
[16,17], the appearance of contrary behavioral symptoms,
Effects of anxiolytics or cannabinoid receptor ligands (can- nabinoids: CBs) on nicotine (NC)-induced depression-related  behavioral alterations Figure 4
Effects of anxiolytics or cannabinoid receptor ligands 
(cannabinoids: CBs) on nicotine (NC)-induced 
depression-related behavioral alterations. The parame-
ter values at 30 min time point are shown for the single (a) 
and repeated (b) NC treatment groups. Data represent 
means ± SD (n = 7 for each group). The symbols for differ-
ences are the same as the other figures. The abbreviations of 
the co-administered anxiolytics or CBs as demonstrated 
below the X-axis are noted in the text.
a) Single NC treatment group 
1. Time until immobility (min)
0
2.5
5
Control NC-only DZ WAY ON AEA ARA VD CP
a a
a
a
a a
2. Activity counts (counts/10min)
0
2000
4000
Control NC-only DZ WAY ON AEA ARA VD CP
a a
a
a
a a a
   
b) Repeated NC treatment group 
1. Time until immobility (min)
0
2.5
5
Control NC-only DZ WAY ON AEA ARA VD CP
a a
a
a
a
a a
2. Activity counts (counts/10min)
0
2000
4000
Control NC-only DZ WAY ON AEA ARA VD CP
a a
a
a
a a a
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for example anxiogenic vs. anxiolytic symptoms, seemed
to be controlled closely by the treatment conditions (i.e.
dose, time after use, previous exposure to NC, etc.). For
example, the antidepressant effects of NC have been
reported to be affected by dose-dependent alterations in
5-HT turnover [34].
Between the single and repeated treatment groups, there
were obvious differences in the time course of NC-
induced anxiety- and depression-related behavioral symp-
toms. In the repeated treatment group, both NC-induced
anxiogenic and depressive effects were prolonged as com-
pared to the single treatment group (Figs. 1 and 2). The
time of the NC-induced anxiolytic effects was also differ-
ent between the single and repeated treatment groups. In
addition to the modified and time-dependent activation
of the HPA axis [33,35], repeated NC-induced prolonged
stimulation of the sympathoadrenal system [36] may con-
tribute to the long-lasting behavioral alterations. Further-
more, in the repeated treatment group, the antagonistic
effects of some CBs observed in the single treatment group
were not seen (Figs. 3 and 4). Although single NC-
induced anxiety-related behavioral symptoms were par-
tially antagonized by selective CB agonists such as ARA
and CP [37,38], repeated NC, like chronic stress [39],
seemed to cause an enhanced stress-related response
which was not antagonized by those CB agonists.
Although the induction of anxiogenic effects has been
reported for CP [40], neither ARA nor CP provided any
anxiogenic or anxiolytic effects in the ARA- or CP-only
group, with the present doses at the selected time points
(see Results section). However, anxiolytic effects were
observed only in the single NC treatment group, unlike
the psychostimulant treatment groups in which both ARA
and CP provided anxiolytic effects in the repeated treat-
ment groups [41]. Repeated NC treatments may specifi-
cally activate other "anxiety-related" brain receptors, in
addition to enhancing stress-related responses.
With respect to the effects of anxiolytics or CBs, the
absence of both antidepressant and depression-enhancing
effects for the BZ- and 5-HT-related anxiolytics was dem-
onstrated in the present study, in spite of the suggested
contribution of GABAergic and 5-HT neurons to the
depressive effects of NC [21,22]. Only VD, a mixed ago-
nistic/antagonistic endocannabinoid [42], provided sig-
nificant antidepressant effects in both single and repeated
treatment groups. Against the anxiogenic effects of NC,
VD provided significant antagonistic effects: the anxiolytic
effects were as strong as WAY, an antagonist of 5-HT1A
receptors for which a direct contribution to the anxiogenic
effects of NC has been suggested [43,44]. Therefore, the
mixed CB agonist/antagonist VD [42] was favorable for
blocking the present NC-induced behavioral effects, com-
pared with the other CBs, which functioned mainly as
brain CB receptor agonists [37,38,45]. In the single treat-
ment group, however, partial antagonistic effects of AEA
restricted to the activity count parameter were provided
against the depressed swimming behaviors. AEA and the
strong selective CB agonists ARA and CP partially attenu-
ated the single NC-induced anxiety-related behavioral
alterations in the elevated plus-maze test. Although the
detailed characteristics of each CB (e.g. indirect target
receptors, etc.) have not been elucidated, the partial antag-
onistic effects of AEA against the depressed swimming
behaviors may be correlated with the presence of specific
effects and/or targets of AEA as previously suggested [46].
Conclusion
The present study demonstrated a chronological overlap
for the anxiogenic and depressive effects of NC. A prolon-
gation of these behavioral effects caused by repeated
administrations and early transient anxiolytic effects
seemed to lead to the reinforcement of habitual use of
NC, similar to other addictive drugs such as harmful psy-
chostimulants.
Among anxiolytics and CBs, the endogenous CB VD,
which is known to act as a mixed agonist/antagonist on
brain CB receptors, attenuated both anxiogenic and
depressive effects of NC. This supports the contribution of
brain CB receptors to NC-induced anxiety- and depres-
sion-related behavioral symptoms. Furthermore, one can
predict that the role of VD as a mixed agonist/antagonist
on brain CB receptors contributed to its double validity as
both an anxiolytic and an antidepressant.
Methods
Animals
Male ICR mice (60–90 days old) (Shizuoka Laboratory
Animal Center, Hamamatsu, Japan) were housed in a
forced-air facility, which was maintained at 23°C and 50
% relative humidity, with a 12 h/12 h light/dark cycle
[47,48]. The mice were kept separately in single transpar-
ent cages measuring 23.5 × 16.5 × 12 cm, and were
allowed water and rodent chow ad libitum [47,48]. The
experiments described in this report were conducted in
accordance with the "Guidelines for Animal Experiments"
of our institution (1988), which are based on the
National Institutes of Health Guide for Care and Use of
Laboratory Animals, and any pain experienced by the
mice was minimized. Each experimental group contained
7 mice.
Drug treatments
Doses of nicotine (NC) (Nacalai Tesque, Inc., Kyoto,
Japan) were determined based on preliminary experi-
ments and previous studies examining its behavioral
effects in single and repeated treatment groups [49,50].
After the preliminary experiments, the doses of NC whichBMC Neuroscience 2007, 8:76 http://www.biomedcentral.com/1471-2202/8/76
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caused anxiogenic and depressive effects most predomi-
nantly were selected. For the single treatment group, a sin-
gle subcutaneous (s.c.) dose of 0.5 mg/kg was
administered. For the repeated treatment group, a s.c.
dose of 0.3 mg/kg was administered daily for 4 days.
The anxiolytics except for CBs were selected among the
drugs which are known to act as anxiolytics and have been
demonstrated to attenuate the effects of NC in prelimi-
nary experiments and previous studies [7,9,51-53]. The
drugs selected were the BZ agonist diazepam (DZ) [51,53]
purchased from Astellas Pharma Inc. (Tokyo, Japan), the
5-HT1A antagonist WAY100135 dihydrochloride (WAY)
[9] purchased from Tocris Cookson Inc. (Ellisville, Mis-
souri, USA), and the 5-HT3 antagonist ondansetron
hydrochloride (ON) [7,52] purchased from GlaxoSmith-
Kline Inc. (London, UK).
As CBs, the endogenous CBs anandamide (arachido-
nylethanolamide: AEA) [45], 2-arachidonylglycerol
(ARA) [38], and virodhamine (VD) [42], and the potent
and synthetic agonist CP 55940 ((-)-cis-3- [2-Hydroxy-4-
(1,1-dimethylheptyl)phenyl]- trans-4-(3-hydroxypro-
pyl)cyclohexanol) (CP) [37], all purchased from Tocris
Cookson Inc., were selected. With respect to these CBs, the
anxiolytic effects except for those provided by AEA [29]
have not been examined sufficiently. However, based on
a study examining the psychostimulant-induced anxiety-
related behavioral symptoms [41], the CBs which pro-
vided some anxiolytic effects against the psychostimulant-
induced symptoms were selected.
With respect to the dose of the anxiolytics and CBs, a sin-
gle dose was selected after preliminary experiments exam-
ining a broad range of concentrations. For each drug, data
were collected for the dose which provided no anxiety-
and depression-related behavioral alterations by itself at
the selected time points, but which antagonized the NC-
induced anxiety-related behavioral symptoms most effec-
tively. For the single treatment group, an intraperitoneal
(i.p.) injection of 5 mg/kg for DZ, 1 mg/kg for WAY, 0.01
mg/kg for ON, 10 mg/kg for each endocannabinoid, or
2.5 mg/kg for CP was performed before the NC treatment.
For the repeated treatment group, an i.p. injection of the
same dose of each anxiolytic and CB was performed
repeatedly before each NC treatment. Except for the CBs,
the anxiolytics were administered 15 min before each NC
treatment [7,9,51-53], whereas the CBs were administered
60 min before each NC [54], based on previous studies
and preliminary experiments.
NC was dissolved in saline to a volume of 5 ml/kg for
administration. Since the CBs and WAY are not soluble in
water, they were initially dissolved in dimethylsulphoxide
(DMSO) (Nacalai Tesque Inc.) to one-third of the total
volume, and then diluted in distilled water to a volume of
5 ml/kg. Since AEA, ARA, and VD were provided in etha-
nol solutions (Tocris Cookson Inc.), the ethanol was
evaporated immediately before use under nitrogen gas,
and the residues were initially dissolved in DMSO to one-
third of the total volume, and then diluted in distilled
water to a volume of 5 ml/kg [55,56]. The other anxiolyt-
ics were also dissolved in DMSO to one-third of the total
volume, and then diluted in distilled water to a volume of
5 ml/kg. In the NC-only group, even in the time course
study of the NC-only treatment, a mixed vehicle solution
of DMSO and distilled water at the same ratio as the solu-
tions of anxiolytics or CBs was injected instead of the anx-
iolytics or CBs, 15 min before each NC administration. In
the anxiolytic- or CB-only groups, the same volumes of
saline vehicle were injected instead of NC. In the control
group without any drug treatment (control group), a
mixed vehicle solution of DMSO and distilled water at the
same ratio as the anxiolytic or CB solutions was injected
instead of the anxiolytics or CBs, and then the same vol-
ume of saline vehicle was injected instead of NC. The drug
administration and each experimental session were per-
formed between 15 and 19 hrs light cycle.
Evaluation of anxiety-related behavioral alterations 
(elevated plus-maze test)
Based on previous studies [41,57], alterations in anxiety-
related behaviors were examined by the elevated plus-
maze test using an apparatus that consisted of two oppo-
site open arms 50 × 10 cm (length and width) and two
closed arms 50 × 10 × 30 cm (length, width, and height).
As parameters for the test (5 min test periods), the number
of entries into open arms, the total number of entries into
arms, the time spent in open arms (sec), and the latency
to first open arm entry (sec) were evaluated. In the time
course study, evaluations of these parameters were per-
formed at 30, 60, and 120 min time points after the NC
treatment. The parameters were evaluated after placing
each mouse diagonally in the center of the maze, facing
both the open and closed arms.
Evaluation of depression-related behavioral alterations 
(forced swimming test)
Based on previous studies [48,58], alterations in depres-
sion-related behaviors were examined by the forced swim-
ming test using a glass cylinder apparatus 33 cm in height
and 18 cm in diameter containing 14 cm of water at 21–
23°C. As parameters for the test, the time until immobil-
ity (the time after when only modest swimming behaviors
necessary to avoid drowning were observed) and the activ-
ity counts for 10 min yielded by swimming behaviors
were evaluated. In the time course study, evaluations of
these parameters were performed at 30, 60, and 120 min
time points after the NC treatment. The activity was
counted using the activity-measuring and recording sys-BMC Neuroscience 2007, 8:76 http://www.biomedcentral.com/1471-2202/8/76
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tem Supermex-CompACT AMS instrument (Muromachi
Kikai Co. Ltd., Tokyo, Japan) by placing the sensor of the
instrument over the cylinder at a distance of 20 cm from
the water.
Statistical analysis
The data obtained were subjected to two-way analysis of
variance (ANOVA) for both single and repeated treatment
groups [41,59]. In the experiments of the time course of
the NC-induced behavioral alterations, a 2 (NC versus
vehicle) × 3 (30 min, 60 min versus 120 min) factorial
design was used for the factors NC treatment × test time.
In the experiments of the effects of the anxiolytics or CBs,
a 2 (NC versus vehicle) × 8 (DZ, WAY, ON, AEA, ARA, VD,
CP versus vehicle) factorial design was used for the factors
NC treatment × treatment of each anxiolytic or CB drug.
The results from ANOVA analyses are summarized in the
table [see Additional file 1]. For pairwise comparisons,
post-hoc Bonferroni tests were performed [41,59]. All of
the comparisons were performed using statistical software
packages ('Excel Statistics' from Social Survey Research
Information Co. Ltd. Inc., Tokyo, Japan). Unless other-
wise noted, P values less than 0.05 were considered to be
statistically significant.
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